Free Trial

10 Best Penny Stocks to Buy Now - 6 of 10

 
 

FibroBiologics (NASDAQ:FBLG)

Number of Upgrades from Top-Ranked Analysts
4 (in the last 90 days)
Consensus Rating
Buy
Rating Score
3.2
Ratings Breakdown
5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$13.00 (1,728.4% Upside)

About FibroBiologics

FibroBiologics logoFibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. More about FibroBiologics
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
6/17/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$16.00
5/15/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$16.00 ➝ $16.00
4/9/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$16.00 ➝ $16.00
4/1/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$16.00 ➝ $16.00
4/1/2025HC WainwrightReiterated RatingBuy ➝ Buy$12.00 ➝ $12.00
2/27/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$16.00 ➝ $16.00
2/13/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$16.00 ➝ $16.00
2/13/2025HC WainwrightReiterated RatingBuy ➝ Buy$12.00 ➝ $12.00
12/27/2024D. Boral CapitalReiterated RatingBuy ➝ Buy$16.00 ➝ $16.00
12/12/2024Rodman & RenshawInitiated CoverageBuy$12.00